Baxter(US:BAX) Businesswire·2025-11-06 17:15Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential securities law violations at Baxter International Inc. following serious safety concerns related to its Novum IQ Large Volume Pump, which has led to significant investor losses and stock price decline [2][3][5]. Group 1: Safety Concerns and Legal Investigation - A Missouri news outlet reported serious safety issues with Baxter's Novum IQ Large Volume Pump, citing a whistleblower who claimed the pumps were unsafe for patient treatment [3]. - Baxter acknowledged potential under infusion risks in warning letters to customers, disclosing one serious injury linked to the device [4]. - The FDA classified the situation as a Class I recall, indicating a severe risk of serious injury or death, with Baxter reporting 79 serious injury cases and two patient deaths associated with the device [4]. Group 2: Stock Price Impact - Following the announcement of a voluntary and temporary pause in shipments and installations of the Novum LVP, Baxter's stock price fell by $6.24 per share, or 22.4%, closing at $21.61 per share on July 31, 2025 [5].